Media coverage about Patheon (NYSE:PTHN) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Patheon earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.9492359524791 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Separately, BidaskClub downgraded shares of Patheon from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $33.60.

Shares of Patheon (NYSE:PTHN) remained flat at $$34.98 on Tuesday. 229,700 shares of the stock traded hands, compared to its average volume of 754,718. Patheon has a 12-month low of $23.72 and a 12-month high of $35.13. The company has a market cap of $5,080.00 and a P/E ratio of 45.43. The company has a debt-to-equity ratio of -7.33, a quick ratio of 0.91 and a current ratio of 1.65.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-patheon-pthn-share-price/1773433.html.

Patheon Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Receive News & Ratings for Patheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon and related companies with MarketBeat.com's FREE daily email newsletter.